212-lead pentixather
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2024 (NCT05557708)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiodepletion
radiodepletion
Chemistry & pharmacology
- Imaging
- 212-Pb
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05557708 | Early Phase 1 (Phase 1) | Jul 1, 2024 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of Iowa |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2024 |
| University of Iowa | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1